cephalexin

cephalexin. It is a first-generation cephalosporin antibiotic used to treat a range of bacterial infections. Developed by Eli Lilly and Company, it is effective against many Gram-positive bacteria and some Gram-negative bacteria. It is commonly prescribed for conditions such as respiratory tract infections, otitis media, skin and skin structure infections, and urinary tract infections.

Medical uses

Cephalexin is indicated for the treatment of infections caused by susceptible organisms. It is frequently used for pharyngitis and tonsillitis caused by Streptococcus pyogenes, as an alternative for patients with penicillin allergy. In dermatology, it is a standard oral therapy for cellulitis and impetigo often stemming from Staphylococcus aureus or Streptococcus pyogenes. For urinary tract infections, it targets pathogens like Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae. It is also employed in treating bone infections such as osteomyelitis caused by susceptible staphylococci and for prophylaxis in certain orthopedic surgery procedures. Its spectrum does not cover notable pathogens like methicillin-resistant Staphylococcus aureus, Enterococcus, or Pseudomonas aeruginosa.

Adverse effects

Common adverse effects are generally mild and involve the gastrointestinal tract, including diarrhea, nausea, vomiting, and abdominal pain. Hypersensitivity reactions can occur, ranging from macular rashes to more severe manifestations like urticaria and, rarely, anaphylaxis; cross-reactivity with penicillin allergies is a consideration. Significant but less frequent effects include Clostridioides difficile infection, which can lead to pseudomembranous colitis, and transient disturbances in liver function tests. Other reported reactions involve the central nervous system (e.g., dizziness, headache), and, very rarely, hematologic changes such as neutropenia and positive Coombs test.

Pharmacology

Cephalexin exerts its bactericidal effect by inhibiting bacterial cell wall synthesis. It binds to specific penicillin-binding proteins located inside the bacterial cell wall, which in turn inhibits the final transpeptidation step of peptidoglycan synthesis. This action leads to osmotic lysis of the bacterium. It is acid-stable and is rapidly absorbed after oral administration, with peak serum concentrations occurring about one hour post-dose. The drug is widely distributed to most tissues and fluids, though it does not achieve therapeutic levels in the cerebrospinal fluid and is therefore not used for meningitis. It is excreted largely unchanged in the urine via glomerular filtration and tubular secretion.

History

Cephalexin was discovered and developed in the 1960s by the pharmaceutical research teams at Eli Lilly and Company. Its development followed the isolation of the first cephalosporin C from the fungus Cephalosporium acremonium by Giuseppe Brotzu at the University of Cagliari. Researchers at the Sir William Dunn School of Pathology in Oxford, including Edward Abraham and Guy Newton, were instrumental in elucidating the structure of cephalosporin C. Cephalexin, as a semi-synthetic derivative, represented a significant advancement as the first orally active cephalosporin, receiving approval from the U.S. Food and Drug Administration in 1970. Its introduction, marketed under the brand name Keflex, provided a broader-spectrum oral alternative to penicillin V.

Society and culture

Cephalexin is available under many brand names worldwide, including Keflex (owned by Eli Lilly and Company), Ceporex, and Ranceph. It is on the World Health Organization's List of Essential Medicines. In the United States, it is available as a generic medication and is frequently prescribed in both human medicine and veterinary medicine. Its widespread use has been influenced by its favorable safety profile and oral bioavailability, though its role has been partially supplanted in some settings by later-generation cephalosporins with expanded spectra. Regulatory bodies like the European Medicines Agency and the Food and Drug Administration continue to monitor its safety and efficacy.